RxDoctor Payments DataLook up a doctor →

Ronald Balkissoon, MD

Pulmonary Disease · Denver, CONPI 1013926468

Payments from drug & device makers

$1,205,080in general payments, 2019–2025

Across 965 payments — averaging $1248.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$584K
  • AstraZeneca$322K
  • Regeneron Healthcare Solutions, Inc.$150K
  • Sanofi$100K
  • Merck$13K
  • Sunovion Pharmaceuticals Inc.$11K
  • plus $25K from 5 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK421$583,630
AstraZeneca289$321,823
Regeneron Healthcare Solutions, Inc.127$150,349
Sanofi75$99,543
Merck13$13,279
Sunovion Pharmaceuticals Inc.7$11,238
Genentech USA, Inc.15$9,259
Novartis5$7,077
Bayer11$6,714
Boehringer Ingelheim1$2,150
Bristol Myers Squibb1$17

How this compares

$1,205,080 in reported general payments places this provider in the 95th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$45,085
Medicare patients
115
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →